An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole; Letrozole
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 06 Jun 2024 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
- 06 Jun 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.